{"disease":{"id":"immunoglobulin-a-nephropathy","name":"immunoglobulin a nephropathy"},"drugs":{"marketed":[{"drug_id":"budesonide","indication_name":"Primary immunoglobulin A nephropathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pulmicort Respules","generic_name":"BUDESONIDE","company_name":"AstraZeneca K.K.","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":"2800","mechanism":""},{"drug_id":"atrasentan","indication_name":"primary immunoglobulin A nephropathy (IgAN)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vanrafia","generic_name":"ATRASENTAN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Vanrafia works by binding to and blocking the activity of a specific receptor involved in the progression of IgAN."},{"drug_id":"atrasentan","indication_name":"primary immunoglobulin A nephropathy (IgAN)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vanrafia","generic_name":"ATRASENTAN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Vanrafia works by binding to and blocking the activity of a specific receptor involved in the progression of IgAN."},{"drug_id":"iptacopan","indication_name":"Primary Immunoglobulin A Nephropathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fabhalta","generic_name":"IPTACOPAN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Factor B","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Iptacopan binds to Factor B, regulating C3 cleavage and downstream effects in the alternative complement pathway, controlling IVH and EVH in PNH and inhibiting local activation in IgAN and C3G."}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06065852","title":"National Registry of Rare Kidney Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"UK Kidney Association","has_results":false},{"nct_id":"NCT04662723","title":"Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":878,"lead_sponsor_name":"Fondazione Schena","has_results":false},{"nct_id":"NCT06564142","title":"Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":605,"lead_sponsor_name":"Alpine Immune Sciences Inc, A Subsidiary of Vertex","has_results":false},{"nct_id":"NCT05248659","title":"Phase 2/3 Open-Label Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy","phase":"PHASE2, PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":600,"lead_sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","has_results":false},{"nct_id":"NCT05248646","title":"Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":530,"lead_sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","has_results":false},{"nct_id":"NCT06291376","title":"Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":510,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT05200871","title":"Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy)","phase":"","overall_status":"COMPLETED","enrollment_count":487,"lead_sponsor_name":"Travere Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06935357","title":"A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":454,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT04573478","title":"Atrasentan in Patients With IgA Nephropathy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":404,"lead_sponsor_name":"Chinook Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05852938","title":"A Study of Zigakibart in Adults With IgA Nephropathy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":383,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06952426","title":"A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04287985","title":"Safety and Efficacy Study of VIS649 for IgA Nephropathy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":155,"lead_sponsor_name":"Visterra, Inc.","has_results":true},{"nct_id":"NCT04564339","title":"Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":123,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT04573920","title":"Atrasentan in Patients With Proteinuric Glomerular Diseases","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":103,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05097989","title":"Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":100,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT07474636","title":"Efficacy and Safety Study of HS-10542 for IgA Nephropathy","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":90,"lead_sponsor_name":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05732402","title":"An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":72,"lead_sponsor_name":"Alpine Immune Sciences, Inc.","has_results":false},{"nct_id":"NCT05003986","title":"Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":67,"lead_sponsor_name":"Travere Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05065970","title":"Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"HI-Bio, A Biogen Company","has_results":false},{"nct_id":"NCT05834738","title":"Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03719443","title":"First in Human Study to Assess Safety of VIS649 in Healthy Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":51,"lead_sponsor_name":"Visterra, Inc.","has_results":true},{"nct_id":"NCT05856760","title":"A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Travere Therapeutics, Inc.","has_results":true},{"nct_id":"NCT07146906","title":"A Study to Assess the Effects of Zigakibart on IgA Nephropathy.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":32,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06994845","title":"Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":31,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07522099","title":"Chinese Adults With Kidney Disease","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"ADARx Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT07498335","title":"Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":28,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07024563","title":"Study of Ravulizumab in Pediatric Participants With Primary IgAN","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT05534919","title":"Efficacy and Safety in Chinese Patients with Immunoglobulin a Nephropathy (IgAN) Who Have Completed Study Nef-301","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Everest Medicines (Singapore) Pte. Ltd.","has_results":false},{"nct_id":"NCT06797518","title":"Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04663204","title":"A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":12,"lead_sponsor_name":"University of Leicester","has_results":false},{"nct_id":"NCT02384317","title":"Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":7,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT05162066","title":"Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"BioCryst Pharmaceuticals","has_results":true},{"nct_id":"NCT02605525","title":"Efficacy and Safety of SM101 in the Treatment of IgA Nephropathy","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Baxalta now part of Shire","has_results":false}],"total":33},"guidelines":[],"source":"Drug Landscape verified database"}